Search

Methods of treating relapsing multiple sclerosis using fenebrutinib 200mg twice daily

USPTO issued Patent US12605376B2 to Genentech, Inc. covering methods of treating Relapsing Multiple Sclerosis using fenebrutinib, a Bruton's tyrosine kinase inhibitor. The patent protects administration of approximately 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof. The patent contains 17 claims and is classified under CPC codes A61K 31/4985, A61P 37/00, and A61P 25/00.